Ird Luxturna denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for ird luxturna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applied a Quantity Limit to Luxturna — and How to Appeal

Luxturna is administered as a single subretinal injection into each eligible eye, typically across two separate procedures. Cigna's quantity limit denial most commonly occurs when the claim reflects bilateral treatment and the plan's quantity policy requires separate authorization for the second eye, or when the timing between procedures falls outside a specified window. This is an administrative and clinical-criteria issue, not a fundamental coverage question, and it is routinely resolved on appeal.

## Federal Appeal Rights

Quantity-limit denials are adverse benefit determinations under federal law. ACA §2719 entitles you to an internal appeal and, if upheld, an independent external review by a certified IRO. ERISA §503 provides additional full-and-fair review rights for employer-sponsored plans. The external review window is generally 4 months from the final internal decision. If the untreated second eye faces rapid vision deterioration, request expedited review — inherited retinal dystrophies can progress irreversibly.

## Concrete Appeal Steps

1. Pull the denial letter and identify exactly which unit or administration sequence triggered the limit. 2. Obtain Cigna's current coverage policy for Luxturna, paying specific attention to the bilateral treatment provisions and any timing requirements. 3. Confirm with the treating retinal specialist that the proposed treatment sequence aligns with what the FDA label and the applicable specialty-society guideline (e.g., American Academy of Ophthalmology) recommend. 4. File the internal appeal with the documentation package below; if denied, move immediately to external review.

## Documentation to Gather

• Genetic documentation: Confirmed lab report showing the qualifying bilateral mutation — this establishes that both eyes are affected and eligible under the FDA-approved indication.
• Bilateral ophthalmologic evaluation: Separate, current clinical assessments of each eye documenting retinal function and viability as required by both the FDA label and Cigna's policy.
• Prescriber letter addressing quantity rationale: The specialist should explain, in writing, the clinical basis for bilateral treatment and the recommended sequence and timing, citing the FDA label and applicable guideline organization.
• Operative reports or scheduling documentation: If the first eye was treated, provide the operative note. For the second eye, provide the proposed scheduling rationale.

## Criteria-Mapping Structure

Review Cigna's quantity policy line by line. For each stated limitation, document the specific clinical fact that shows your case either meets the limit's conditions or qualifies for the exception pathway. Submit this as a structured attachment. Quantity-limit denials that are accompanied by complete bilateral clinical documentation have a strong track record at external review because the FDA label itself contemplates bilateral administration.